Maternal-fetal transmission of human immunodeficiency virus type 1 (HIV-1) is currently responsible for the majority of cases of pediatric HIV infection. Prospective epidemiologic studies in different geographic locations have demonstrated variability in transmission rates ranging from 13% to 40% [1] . Transmission may occur intrapartum, in utero, or through breast-feeding [2] . Some 50%-70% of infants with ultimately documented HIV infection have negative virus results at birth, with later positive cultures at 2-8 weeks of age, suggesting transmission at the time of labor and delivery [3] . Selected studies have identified HIV in the genital secretions of .--30% of HIV-infected women [4] ; however, there are currently few reliable parameters for predicting transmission except for a low maternal CD4 cell count and evidence of a high virus load [5, 6] . Recently, the use of zidovudine given to the mother during pregnancy, labor, and delivery followed by a 6-week course of antiretrovira1 therapy in the infant has been shown to reduce the risk of vertical transmission from 25.5% to 8% [7] . Transmission of HIV from mother to infant during labor and delivery may be influenced in part by local factors in the genital mucosa, such as the presence or absence of HIV-1 specific secretory (s) IgA in cervicovaginal secretions (CVS). The identification of additional sources of virus exposure might further our understanding of the pathogenesis of HIV-1 transmission by the intrapartum route and potentially aid in the obstetric and pediatric management of HIV-infected women and their infants.
Methods
Study design. A prospective cohort design was used to investigate the presence of HIV-specific antibodies and HIV-1 in CVS of seropositive pregnant women receiving prenatal care at UCLA. Cervicovaginal specimens were collected during the third trimester of pregnancy and close to delivery when possible. Clinical, laboratory, and therapeutic data were obtained longitudinally during the course of gestation, labor, and delivery. Gastric aspirates were obtained from infants at delivery. All infants were followed prospectively from birth for determination of HIV infection status by viral culture and polymerase chain reaction (peR). Infants were characterized as infected in utero or intrapartum using the current working definition for timing of vertical HIV infection in nonbreast-fed children [8] . In parallel, the presence of HIV and specific antibodies in CVS of HIV-infected nonmenstruating mothers receiving medical care at UCLA was evaluated.
Samples for HIV antibody assays were collected directly from the vaginal vault by a pipette before wash. Cervicovaginal cells were collected after a vaginal wash with 15 mL of RPMI 1640 (Life Technologies GIBCD BRL, Gaithersburg, MD) during pelvic examination. Supernatants were centrifuged for 10 min with cell pellets resuspended in RPMI 1640. The cell suspension was equally divided and processed for immediate HIV-1 coculture, HIV-1 DNA PCR, and storage in liquid nitrogen.
HIV-l coculture of cervicovaginal cells and gastric aspirates. One milliliter of RPMI 1640 medium containing one-third of the cervicovaginal cells originally collected was transferred to a culture vial and processed according to standard macrococulture techniques. Infant gastric aspirates were obtained immediately after delivery by a DeLee suction trap and similarly cultured.
HIV DNA PCR of cervicovaginal cells. Quantitative HIV-l DNA PCR was done as described [9] .
Immune complex-dissociated HIV p24 antigen assay on CVs. Immune complex disruption procedure was done on lOa-ilL aliquots ofCVS diluted in RPMI 1640 using a commercially available kit (Abbott, Abbott Park, IL).
Anti-HIV IgA dot blot analysis. HIV-1-specific IgG and IgA were detected using an immunoblot assay [10] .
HIV-l RNA PCR. Maternal virus load at delivery was measured on previously frozen plasma specimens by batch testing using RNA PCR (AMPLICOR HIV MONITOR assay) according to the manufacturer's instructions (Roche Molecular Systems, Somerville, NJ).
Results
Twenty-seven HIV-infected women were enrolled in the study (21 pregnant and 7 nonpregnant mothers, including 1 who had CVS collected during pregnancy and after delivery). Pregnant and nonpregnant subjects had similar ages (pregnant: mean, 24.7 years; range, 15-34; nonpregnant: mean, 23.7 years; range, 19-27). Among pregnant subjects, 37 of39 serial samples were collected during the last month of gestation, while for nonpregnant subjects, specimen collection was done once. Most subjects had asymptomatic HIV infection (17 of 21 pregnant and 5 of 7 nonpregnant). Pregnant subjects had a slightly higher mean CD4 cell count (643/mm 3 ; range, 129-1871) than did nonpregnant subjects (429/mm 3 ; range, 175-990). Eighteen pregnant and only 2 nonpregnant subjects were receiving zidovudine. Most pregnant subjects (19/21) had uncomplicated vaginal deliveries. Twenty-two infants were born (1 pair of twins). Four of these infants were perinatally HIVinfected (3 in utero and 1 intrapartum). Nonpregnant mothers were 2-26 months postpartum. Eight children (1 pair oftwins), 2 of whom were HIV-infected, had been born to them.
Of the 27 women originally enrolled, 25 (93%) had either HIV-1 culture, PCR, or both procedures done on CVS. Overall, HIV-l was identified by culture, PCR, or both in 7 (28%) (table 1): 3 (43%) of 7 nonpregnant and 4 (21%) of 19 pregnant women. None of the 46 immune complex-dissociated p24 antigen assays were positive. Sequential CVS samples from 1 patient who had a positive HIV PCR result before zidovudine treatment at 15 weeks of gestation showed no evidence of virus by PCR 1 week before delivery. All 4 pregnant subjects with detectable HIV in CVS during pregnancy delivered uninfected infants (1 woman with identifiable HIV in CVS 2 weeks before delivery had twins by cesarean delivery, 1 had HIV in CVS at 15 weeks of gestation and no identifiable virus in CVS at delivery, 1 with identifiable virus 1 day before delivery did not transmit HIV to her infant, and 1 had HIV identified in CVS at 15 and 10 days before delivery but no HIV detected 4 days before her infant's birth).
Serial CVS specimens from 24 (89%) of 27 subjects (18 pregnant and 6 nonpregnant) were assayed for the presence of IgG and sIgA. All had HIV-specific IgG antibodies in their CVS (anti-gpI60 in 100%, anti-p66 in 92%, anti-p24 IgG in 48%; none had anti-gpl20 IgG detected). HIV-specific sIgA was present in the CVS of 10 (42%) of 24 women, 8 (44%) of 18 pregnant and 2 (33%) of 6 nonpregnant. All 10 had sIgA anti-gpI60, 5 had additional anti-p66 sIgA, and 1 had antigp120 sIgA. No anti-p24 sIgA was detected. Of the 7 who had identifiable virus in CVS, 3 had sIgA concurrently, 3 had no sIgA, and 1 did not have immunoblot analysis done. Among the 4 who transmitted HIV infection to their infants, 2 had no detectable sIgA in CVS before delivery, 1 had sIgA anti-gp160, and 1 was not tested for sIgA.
HIV-1 gastric aspirates from 16 neonates were cultured. None of the gastric aspirates were noted to be visibly bloody. Among the HIV-infected infants, 2 of 4 had a positive gastric aspirate culture, while all 12 uninfected children had negative cultures. In 1 infant with a positive gastric aspirate culture, perinatal transmission most likely occurred intrapartum as evidenced by negative peripheral blood lymphocyte cultures and HIV-1 DNA PCR within 48 h with subsequent positive cultures and PCR 2 weeks later. The other infant with a positive gastric aspirate culture probably had late acquisition of HIV infection (in utero or during labor), since peripheral blood lymphocyte cultures were positive twice within the first 48 h of life and HIV RNA PCR copy number was also low at that time (100 copies/mL). HIV-l DNA PCR did not become positive until 2 months after delivery. Of note, the other 2 infected infants had positive peripheral blood lymphocyte HIV-1 cultures and HIV-1 DNA PCR from peripheral blood within 48 h of life and negative gastric aspirate cultures.
The mother of the infant with presumed intrapartum infection had negative HIV CVS culture 2 weeks before delivery and a positive HIV-1 CVS culture at 6 months postpartum. The mother of the other infant with a positive gastric aspirate had no identifiable virus in CVS on the week of delivery. Likewise, the mothers of the other 2 presumably in uteroinfected infants who had negative gastric aspirate cultures also had no identifiable virus in CVS. Only 1 of the 4 mothers who transmitted infection received zidovudine therapy during gestation, labor, and delivery, while all of the remaining nontransmitters received zidovudine during gestation. Consistent with our previous findings, the maternal virus load as measured by HIV RNA PCR at delivery was higher among the 4 transmitters (mean, 68,921 copies/mL of plasma; range, 28,999-92,207) than among the 15 nontransmitting mothers (mean, 9457 copies/mL of plasma; range, 100~67,862); however, cervical viral shedding did not necessarily corre- late with peripheral blood HIV levels (mean HIV RNA copy number among 4 pregnant subjects with HIV in CVS was 5498 copies/mL of plasma; range, 638-15,011). Only 1 of the 4 transmitting mothers with high levels of viremia had detectable HIV in CVS; however, virus was detectable only 6 months after delivery in this mother. Table 2 demonstrates the relationship between a positive gastric aspirate culture and maternal factors.
Discussion
We found that more than one-quarter of HIV-infected women we studied had evidence of HIV in CVS, with less detection in pregnant women (21 %) compared with nonpregnant women (43%) than previously reported. This may be explained in part by the relatively high mean CD4 cell count of pregnant subjects and the widespread use of zidovudine in this population (16/19 [84%] vs. 2/7 [29%]). Zidovudine has been found at low concentrations in CVS and at higher concentrations in amniotic fluid of HIV-infected pregnant women after oral therapy [11] . When HIV was detected in cervicovaginal cells, the virus load was relatively low, with a mean HIV DNA copy number of 16/J-lg of DNA and a minimum of 21 days for cultures to become positive, which also indicated a low virus burden. In addition, maternal virus levels in plasma did not necessarily correlate with HIV shedding in CVS. Women with a high virus burden and no zidovudine treatment had no virus detectable in CVS; conversely, a subgroup who had low plasma viremia was found to have intermittent low-level CVS shedding ofHIV. HIV-1 was isolated from infant gastric aspirates from 2 of 4 HIV-infected neonates who were vaginally delivered and from none of the uninfected infants. One of these infants had intrapartum acquisition of infection, while the other most probably acquired infection before birth. This second infant had a low virus load at birth and in the first week of life by culture and HIV RNA PCR. .In addition, DNA PCR results did not become positive until 2 months after delivery, with no detectable immune complex-dissociated p24 antigenemia to date (21 months). These findings suggest transmission of the virus late in the course of gestation. The fact that 2 of the in uteroinfected infants had negative gastric aspirates despite high maternal plasma virus loads as measured by HIV RNA PCR assays suggests that there may not be a direct correlation between peripheral virus load and shedding of HIV in CVS. In addition, all uninfected infants who were born by vaginal delivery had gastric aspirates that were negative for HIV, suggesting that oral contamination with infected maternal secretions is not a general phenomenon. Recently, a third infant born to an HIVinfected pregnant woman followed in our ongoing maternalfetal transmission studies has had a gastric aspirate culture positive for HIV at delivery (data not shown) with cord, day 1, and day 7 peripheral blood specimens having detectable HIV (by culture and PCR). Therefore, the presence of HIV-I in the gastric aspirates of HIV-infected infants may indicate that these infants could potentially be infected during delivery by swallowipg ofHIV-infected blood, maternal CVS, or amniotic fluid. In these cases, we found no obvious contamination of specimens with blood; however, this does not rule out microscopic blood contamination. Exposure of the infant to maternal blood has been demonstrated to be significantly associated with an increased risk of maternal-fetal transmission, as has prolonged rupture of membranes (>4 h), resulting in exposure to potentially infected maternal CVS; the use of cesarean section may also protect against transmission [12] . Our results are consistent with those of other investigators, who reported the successful infection of 4 newborn rhesus monkeys with SIV by oral inoculation of a cell-free SIV solution immediately after delivery [13] . Therefore, a positive gastric aspirate in the neonate may be an important risk factor for HIV infection.
We detected HIV-1-specific slgA in the genital tracts of fewer than half of our subjects. In 3 from whom HIV was isolated in CVS, HIV-specific slgA antibodies were detected concurrently, suggesting that the antibody present was not neutralizing the virus. Although serum IgA neutralization of HIV-1 isolates has been reported [14] , the neutralizing capability of HIV-specific slgA remains to be determined. The presence of HIV-specific slgA in genital secretions has been reportedly associated with an increased risk of vertical transmission [15] . Although we observed no correlation, because of the small sample size in this study, we could not make any conclusions regarding the role of CVS antibodies in perinatal HIV transmission.
This pilot study showed that virus can be found both in maternal CVS and in the infant's first gastric aspirate immediately after delivery. A relatively low incidence of viral shedding in CVS was observed, and this did not correlate with maternal plasma HIV levels. Further prospective studies will be necessary to correlate the risk of transmission with HIV-1 shedding, presence of slgA, and detectable HIV-1 in the infant's gastric aspirate.
